financetom
Business
financetom
/
Business
/
What's Going On With Abercrombie & Fitch Stock Today?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Abercrombie & Fitch Stock Today?
Aug 29, 2024 9:25 AM

Abercrombie & Fitch Co ( ANF ) shares are trading lower after the company reported second-quarter earnings.

Sales grew 21% Y/Y to $1.134 billion, beating the analyst consensus estimate of $1.101 billion. Comparable sales jumped 18% Y/Y. Adjusted EPS of $2.50 beat the analyst consensus estimate of $2.22.

Americas sales increased 23%, EMEA grew 16% and, APAC sales climbed 3% Y/Y. Abercrombie brand sales rose 26%, while Hollister sales improved 17% Y/Y.

Gross profit margin expanded 240 basis points Y/Y to 64.9% in the quarter. Operating expense, excluding other operating income, net of $561 million for the quarter, with the operating expenses ratio improving to 49.4% from 53.2% last year.

Operating income for the quarter was $176 million versus $90 million a year ago, with a margin expansion of 590 basis points Y/Y to 15.5%.

As of August 3, the company held $738 million in cash and equivalents. The operating cash flow was $260 million for the year-to-date period ended August 3. Inventories were $540 million, compared to $493 million as of July 29, 2023.

Fran Horowitz, Chief Executive Officer, said, “Although we continue to operate in an increasingly uncertain environment, we remain steadfast in executing our global playbook and maintaining discipline over inventory and expenses.”

Outlook: Abercrombie expects third-quarter net sales to grow in the low double digits year over year. The company projects an operating margin of 13% – 14%, compared to 13.1% last year.

Abercrombie & Fitch ( ANF ) raised its FY24 net sales growth outlook to 12% to 13% (from around 10%) and revised the operating margin forecast to 14% – 15% from the prior view of around 14%. The company continues to expect capital expenditure of about $170 million.

Investors can gain exposure to the stock via Tidal Trust II YieldMax Ultra Option Income Strategy ETF  and Invesco Dorsey Wright Consumer Cyclicals Momentum ETF .

Price Action: ANF shares are down 10% at $149.95 premarket at the last check Wednesday.

Read Next:

Nasdaq, S&P 500 Futures Flatline As Traders Await Earnings Report From AI Barometer Nvidia: Fund Manager Says Market Could Hold Up Until Presidential Election

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Exelixis Q3 revenue beats analyst expectations
Exelixis Q3 revenue beats analyst expectations
Nov 4, 2025
Overview * Exelixis ( EXEL ) Q3 revenue of $597.8 mln beats analyst expectations * Adjusted net income for Q3 beats consensus * Company announces $750 mln stock repurchase program Outlook * Exelixis ( EXEL ) raises 2025 total revenue guidance to $2.30 bln-$2.35 bln * Company lowers 2025 R&D expenses forecast to $850 mln-$900 mln * Exelixis ( EXEL...
Latham Group misses Q3 sales estimates, narrows 2025 net sales guidance
Latham Group misses Q3 sales estimates, narrows 2025 net sales guidance
Nov 4, 2025
Overview * Latham Group ( SWIM ) Q3 net sales grow 7.6% but miss analyst expectations * Adjusted EBITDA for Q3 beats analyst estimates, reflecting strong operational performance * Gross margin expanded by 300 basis points due to acquisitions and operational efficiencies Outlook * Latham narrows 2025 net sales guidance to $540-$550 mln * Adjusted EBITDA guidance for 2025 revised...
Cellular therapy developer Longeveron's Q3 net loss widens
Cellular therapy developer Longeveron's Q3 net loss widens
Nov 4, 2025
Overview * Net loss for Q3 widened to $7.2 mln, driven by increased R&D expenses * Company anticipates pivotal trial results for laromestrocel in 2026, potential BLA submission in 2027 Result Drivers * REVENUE DECLINE - Decrease in revenue driven by reduced demand for Bahamas Registry Trial and contract manufacturing services * R&D EXPENSES - Increase in R&D expenses due...
AI lending platform Upstart Q3 revenue rises
AI lending platform Upstart Q3 revenue rises
Nov 4, 2025
Overview * Upstart Q3 revenue rises 71% YoY, driven by 80% growth in loan originations * GAAP net income for Q3 improves to $31.8 mln from a loss last year * Adjusted EBITDA for Q3 increases to $71.2 mln, reflecting operational efficiency Outlook * Upstart expects Q4 2025 revenue of approximately $288 mln * Company anticipates Q4 2025 GAAP net...
Copyright 2023-2026 - www.financetom.com All Rights Reserved